DY
BMY.RT

Dowling & Yahnke’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Dowling & Yahnke’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-20,239
Closed -$14K – 345
2020
Q4 		$14K Sell
20,239
-5,740
-22% -$12.2K ﹤0.01% 328
2020
Q3 		$58K Sell
25,979
-2,145
-8% -$6.13K ﹤0.01% 302
2020
Q2 		$101K Hold
28,124
– – 0.01% 294
2020
Q1 		$107K Buy
28,124
+1,684
+6% +$5.55K 0.01% 285
2019
Q4 		$80K Buy
+26,440
New +$68.8K 0.01% 306

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.61B AUM 22.15% 1-Year Est. Return
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

Dowling & Yahnke's BMY.RT Position: Q1 2021 in Review

Dowling & Yahnke sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 20,239 shares — an estimated $14K sold.

Dowling & Yahnke first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $107K in Q1 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Dowling & Yahnke reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Dowling & Yahnke sold 20,239 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $14K.
  • Dowling & Yahnke first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
  • Dowling & Yahnke's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $107K in Q1 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Dowling & Yahnke's 13F filing for Q1 2021, filed 29 Apr 2021.